Depelestat
Alternative Names: Debio 9701; DX 890; Engineered protein inhibitor of human neutrophil elastase; EPI-HNE4; ReltranLatest Information Update: 15 Dec 2009
At a glance
- Originator Dyax
- Developer Debiopharm; Dyax
- Class Peptides; Recombinant proteins
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute lung injury; Chronic obstructive pulmonary disease; Cystic fibrosis; Respiratory distress syndrome
Most Recent Events
- 04 May 2006 Preclinical trials in Chronic obstructive pulmonary disease (unspecified route)
- 04 Jan 2006 Depelestat has been licensed to Debiopharm worldwide for cystic fibrosis and acute respiratory distress syndrome
- 07 Nov 2005 Phase-I clinical trials in Respiratory distress syndrome in Europe (IV)